5α还原酶抑制剂在前列腺癌化学预防中的作用

Role of 5α-reductase Inhibitors in the Chemoprevention of Prostate Cancer

前列腺癌是人类最常见的内脏恶性肿瘤之一,近年我国的发病率呈逐年上升趋势,5α还原酶抑制剂通过抑制睾酮向二氢睾酮的转化,阻断二氢睾酮的生物学效应,因此可以作为前列腺癌的化学预防药物。完成于2003年及2008年的全世界最大规模的两项关于前列腺癌化学预防的大型临床试验—前列腺癌预防试验和度他雄胺减少前列腺癌事件试验,带来了前所未有的对前列腺癌化学预防的关注,但是学术界对上述试验的结论以及应该给予患者怎样的建议仍然存在争论。

Prostate cancer is one of the most common visceral malignancies in human.In recent years,its incidence has dramatically increased in China.5α-reductase inhibitors can block the biological effects of dihydrotestesterone by restraining the transformation from testosterone to dihydrotestesterone,and therefore can be used for the chemoprevention of prostate cancer.Two large clinical trials on the chemoprevention of prostate cancer（the Prostate Cancer Prevention Trial and the Reduction by Dutasteride of Prostate Cancer Events） were completed in 2003 and 2008,respectively,bringing the global interests on this topic.However,the interpretations of these two trials and the possible recommendations on clinical applications remain controversial.